BIO GREEN MED SOLUTION INC (BGMS)
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-09-09
$0.85-2.06%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-09-09
Broken: Primary pillar broken — Grow revenue through strategic agreements: rev $336.0k vs $743.0k target.
BGMS grew revenue from $29,000 to $743,000 in one year. It raised $794,403 from a key securities deal. The company pays $0.15 quarterly dividend on preferred stock. It works on legal issues to keep its Nasdaq listing.
BGMS is still losing money and has negative cash flow. It faces legal and regulatory problems. The stock price dropped 41% from its high. Capital allocation is mixed with unregistered equity sales.
The price is about 60% below our fair value near $2. The market expects negative growth over 3 to 5 years. Our view is cautious given the company’s losses and risks.
Breaks if: operating cash flow remains negative beyond 2026-Q4
Breaks if: Nasdaq delisting or unresolved litigation by 2027
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and has volatile management, which adds to the uncertainty of its long-term prospects.
The market appears to price in a low level of fragility, suggesting that investors are not overly concerned about immediate risks. BGMS is considered cheap compared to its peers, but the low confidence in valuation models indicates that expectations may not be firmly established.
Management has prioritized completing a business combination and expanding fire safety offerings, but recent performance has shown mixed results. While cost structure improvements are underway, the trajectory remains behind expectations, which could impact future performance.
The long-term thesis hinges on the successful completion of the business combination and the ability to expand product offerings. Additionally, the performance of sector bellwethers will be crucial, as their results could significantly influence BGMS's momentum.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Respond to Nasdaq delisting notice and other regulatory matters affecting preferred stock listing and compliance.
Stated as a priority in 2 of last 2 quarters. Management disclosed the suspension and delisting of the preferred stock from Nasdaq in 2026-Q1 and referenced ongoing regulatory challenges. The company continues to address these issues, with limited progress reported so far.
“Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard received in September 2025.”
“Trading of the Company’s 6% Convertible Exchangeable Preferred Stock was suspended and delisted from Nasdaq in March 2026.”
Breaks if: revenue falls below $743,000 in any quarter after 2026-Q1
Over the next 1 to 3 years, BGMS faces a complex landscape with both opportunities and risks. The execution of management strategies and external market conditions will be key factors to watch. Not investment advice.